Efficacy and Safety of Low-Dose Prasugrel Versus Clopidogrel in Patients with Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention: a Systematic Review and Meta-analysis

被引：0
作者：
Yuttana Wongsalap
Supakorn Ungsriwong
Wanalee Kumtep
Surasak Saokaew
Vichai Senthong
Kirati Kengkla
机构：
[1] University of Phayao,School of Pharmaceutical Sciences
[2] University of Phayao,Division of Pharmacy Practice, Department of Pharmaceutical Care, School of Pharmaceutical Sciences
[3] University of Phayao,Center of Health Outcomes Research and Therapeutic Safety (Cohorts), School of Pharmaceutical Sciences
[4] University of Phayao,Unit of Excellence On Clinical Outcomes Research and IntegratioN (UNICORN), School of Pharmaceutical Sciences
[5] Monash University Malaysia,Biofunctional Molecule Exploratory Research Group, Biomedicine Research Advancement Centre, School of Pharmacy
[6] Selangor Darul Ehsan,Novel Bacteria and Drug Discovery Research Group, Microbiome and Bioresource Research Strength, Jeffrey Cheah School of Medicine and Health Sciences
[7] Monash University Malaysia,Department of Medicine, Faculty of Medicine
[8] Selangor DarulEhsan,undefined
[9] Khon Kaen University,undefined
来源：
Cardiovascular Drugs and Therapy | 2022年 / 36卷
关键词：
Prasugrel; Low dose; Acute coronary syndrome; Percutaneous coronary intervention; Bleeding; Major adverse cardiac events;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：991 / 1000
页数：9
相关论文
共 215 条
[1]  
Levine GN(2016)2016 ACC/AHA guideline focused update on duration of dual antiplatelet therapy in patients with coronary artery disease: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines J Am Coll Cardiol 68 1082-1115
[2]  
Bates ER(2018)2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS) Eur Heart J 39 213-260
[3]  
Bittl JA(2019)Updated expert consensus statement on platelet function and genetic testing for guiding P2Y(12) receptor inhibitor treatment in percutaneous coronary intervention JACC Cardiovasc Interv 12 1521-1537
[4]  
Brindis RG(2005)Clopidogrel and ticlopidine: P2Y12 adenosine diphosphate-receptor antagonists for the prevention of atherothrombosis Semin Thromb Hemost 31 174-183
[5]  
Fihn SD(2009)Pharmacodynamic assessment of platelet inhibition by prasugrel vs. clopidogrel in the TRITON-TIMI 38 trial European Heart Journal 30 1753-1763
[6]  
Fleisher LA(2007)Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2001-2015
[7]  
Valgimigli M(2018)Comparison of prasugrel versus clopidogrel in Korean patients with acute myocardial infarction undergoing successful revascularization J Cardiol 71 36-43
[8]  
Bueno H(2019)Safety and effectiveness of contemporary P2Y(12) inhibitors in an East Asian population with acute coronary syndrome: a nationwide population-based cohort study J Am Heart Assoc 8 1085-1196
[9]  
Byrne RA(2019)JCS 2018 Guideline on diagnosis and treatment of acute coronary syndrome Circ J 83 823-833
[10]  
Collet JP(2013)Elderly patients with acute coronary syndromes managed without revascularization: insights into the safety of long-term dual antiplatelet therapy with reduced-dose prasugrel versus standard-dose clopidogrel Circulation 128 1684-1692
12345678910